GlobeNewswire Inc | Jan 7, 2022 04:05PM EST

January 07, 2022

CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Foghorn will present at the H.C. Wainwright BioConnect Conference which is being held virtuallyon January 10th through the 13th, 2022. With an initial focus in oncology, Foghorns Gene Traffic Control Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

H.C. Wainwright BioConnect Conference Format: Presentation Date: Monday, January 10, 2022 and will be available for 90 daysAll company presentations will be available on-demand beginning at 7:00am ETPlease find a link to the presentation here.

A webcast of the presentation can also be accessed under Events & Presentations in the Investors section of the Companys website, www.foghorntx.com.

AboutFoghornTherapeuticsFoghornTherapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control platform, Foghorn is systematically studying, identifying and validating potential drug targets within the chromatin regulatory system. The company is developing multiple product candidates in oncology with two currently being investigated in clinical studies.

Contact:

Ben Strain, Foghorn Therapeutics (Media and Investors)bstrain@foghorntx.com

Gregory Kelley, Ogilvy (Media)gregory.kelley@ogilvy.com

Hans Vitzthum, LifeSci Advisors (Investors)hans@lifesciadvisors.com